2.Incidence and Mortality of Liver Cancer in Zhejiang Cancer Registration Areas in 2021 and Trends from 2000 to 2021
Jiasheng QIN ; Rong CHEN ; Yang FANG ; Jiawei LI ; Wenzhu XU ; Huizhang LI ; Lingbin DU
China Cancer 2025;34(11):838-846
[Purpose]To analyze the incidence and mortality of liver cancer in cancer registration areas of Zhejiang Province in 2021 and the epidemiological trends of liver cancer from 2000 to 2021.[Methods]Using liver cancer data from 2000 to 2021 reported by Zhejiang Provincial Can-cer Registries,stratified by sex,age,and urban-rural areas,indicators including crude incidence rate,crude mortality rate,age-standardized incidence rate by Chinese standard population(ASIRC),age-standardized mortality rate by Chinese standard population(ASMRC),age-standardi-zed incidence rate by world standard population(ASIRW),age-standardized mortality rate by world standard population(ASMRW)were calculated.Joinpoint Regression Program(Version 5.3.0)was used to fit the log-linear relationship between rates and years,and calculate the annual percentage change(APC)and average annual percentage change(AAPC)with 95%confidence interval(CI).[Results]In 2021,the crude incidence rate of liver cancer in Zhejiang cancer registration areas was 26.93/105(ASIRC:13.35/105),and the crude mortality rate was 20.87/105(ASMRC:9.52/105).The number of new cases and deaths of liver cancer accounted for 5.07%and 11.33%of all malig-nant tumor cases and deaths,respectively.The incidence and mortality rates of liver cancer in male were significantly higher than those in female(crude incidence rate:40.17/105 vs 13.85/105;ASIRC:20.60/105 vs 6.34/105;crude mortality rate:30.78/105 vs 11.07/105;ASMRC:14.67/105 vs 4.57/105),and those in rural areas were higher than those in urban areas(crude incidence rate:30.39/105 vs 24.79/105;ASIRC:15.35/105 vs 12.10/105;crude mortality rate:24.32/105 vs 18.72/105;ASMRC:11.30/105 vs 8.40/105).In 2021,the incidence rate of liver cancer was low before the age of 30 years old,and increased significantly with age after 30 years old,reaching the peak in male aged 85 years old and above(170.04/105)and in female aged 80~84 years old(84.74/105).The mortality rate showed a similar trend to the incidence rate,which was low before the age of 30 years old and increased significantly with age after 30 years old,peaking in male aged 85 years old and above(211.64/105)and in female aged 80~84 years old(98.31/105).From 2000 to 2021,the crude incidence rate of liver cancer in Zhejiang Province showed an overall upward trend(AAPC=1.01%,95%CI:0.44%~1.58%),while the ASIRC remained relatively stable(AAPC=-0.81%,95%CI:-1.48%~0.02%)with a significant remained relatively stable(AAPC=-0.81%,95%CI:-1.48%~0.02%),after 2010,the ASIRC remained relatively stable(AAPC=-0.81%,95%CI:-1.48%~0.02%)with a significant decreased significantly.Both the crude mortality rate(AAPC=-0.84%,95%CI:-1.23%~-0.36%)and ASMRC(AAPC=-2.78%,95%CI:-3.28%~-2.20%)showed sig-nificant downward trends,and the decline of ASMRC was more obvious.[Conclusion]From 2000 to 2021,the incidence of liver cancer in cancer registration areas of Zhejiang Province showed a fluctuating downward trend,and the mortality showed a steady downward trend,but the disease burden remains heavy.Rural areas,the elderly,and males are high-risk populations,which should be the key targets of liver cancer prevention and control.
3.Incidence and Mortality of Liver Cancer in Zhejiang Cancer Registration Areas in 2021 and Trends from 2000 to 2021
Jiasheng QIN ; Rong CHEN ; Yang FANG ; Jiawei LI ; Wenzhu XU ; Huizhang LI ; Lingbin DU
China Cancer 2025;34(11):838-846
[Purpose]To analyze the incidence and mortality of liver cancer in cancer registration areas of Zhejiang Province in 2021 and the epidemiological trends of liver cancer from 2000 to 2021.[Methods]Using liver cancer data from 2000 to 2021 reported by Zhejiang Provincial Can-cer Registries,stratified by sex,age,and urban-rural areas,indicators including crude incidence rate,crude mortality rate,age-standardized incidence rate by Chinese standard population(ASIRC),age-standardized mortality rate by Chinese standard population(ASMRC),age-standardi-zed incidence rate by world standard population(ASIRW),age-standardized mortality rate by world standard population(ASMRW)were calculated.Joinpoint Regression Program(Version 5.3.0)was used to fit the log-linear relationship between rates and years,and calculate the annual percentage change(APC)and average annual percentage change(AAPC)with 95%confidence interval(CI).[Results]In 2021,the crude incidence rate of liver cancer in Zhejiang cancer registration areas was 26.93/105(ASIRC:13.35/105),and the crude mortality rate was 20.87/105(ASMRC:9.52/105).The number of new cases and deaths of liver cancer accounted for 5.07%and 11.33%of all malig-nant tumor cases and deaths,respectively.The incidence and mortality rates of liver cancer in male were significantly higher than those in female(crude incidence rate:40.17/105 vs 13.85/105;ASIRC:20.60/105 vs 6.34/105;crude mortality rate:30.78/105 vs 11.07/105;ASMRC:14.67/105 vs 4.57/105),and those in rural areas were higher than those in urban areas(crude incidence rate:30.39/105 vs 24.79/105;ASIRC:15.35/105 vs 12.10/105;crude mortality rate:24.32/105 vs 18.72/105;ASMRC:11.30/105 vs 8.40/105).In 2021,the incidence rate of liver cancer was low before the age of 30 years old,and increased significantly with age after 30 years old,reaching the peak in male aged 85 years old and above(170.04/105)and in female aged 80~84 years old(84.74/105).The mortality rate showed a similar trend to the incidence rate,which was low before the age of 30 years old and increased significantly with age after 30 years old,peaking in male aged 85 years old and above(211.64/105)and in female aged 80~84 years old(98.31/105).From 2000 to 2021,the crude incidence rate of liver cancer in Zhejiang Province showed an overall upward trend(AAPC=1.01%,95%CI:0.44%~1.58%),while the ASIRC remained relatively stable(AAPC=-0.81%,95%CI:-1.48%~0.02%)with a significant remained relatively stable(AAPC=-0.81%,95%CI:-1.48%~0.02%),after 2010,the ASIRC remained relatively stable(AAPC=-0.81%,95%CI:-1.48%~0.02%)with a significant decreased significantly.Both the crude mortality rate(AAPC=-0.84%,95%CI:-1.23%~-0.36%)and ASMRC(AAPC=-2.78%,95%CI:-3.28%~-2.20%)showed sig-nificant downward trends,and the decline of ASMRC was more obvious.[Conclusion]From 2000 to 2021,the incidence of liver cancer in cancer registration areas of Zhejiang Province showed a fluctuating downward trend,and the mortality showed a steady downward trend,but the disease burden remains heavy.Rural areas,the elderly,and males are high-risk populations,which should be the key targets of liver cancer prevention and control.
4.Effects of CD44 Antigen on Drug Resistance of Breast Cancer Patients
Peizhi LU ; Huizhang YANG ; Juan DU ; Yong JIN
China Pharmacy 2016;27(5):686-688
OBJECTIVE:To evaluate the effect of CD44 on drug resistance of breast cancer patients. METHODS:62 breast cancer patients were selected,and the expression of CD44 was detected by immunohistochemical method. Drug resistance was eval-uated by WHO criteria,and the expression of CD44 in breast tissue was observed after observation. RESULTS:There were 48 pa-tients sensitive to CD44 and 14 patients with drug resistance,with statistical significance(P<0.05). After chemotherapy,the ex-pression of CD44 in caner tissue was higher than before chemotherapy,that of patients with drug resistance was higher than pa-tients sensitive to CD44,with statistical significance(P<0.01). CONCLUSIONS:CD44 antigen is closely related to chemothera-py resistance of breast cancer,and high expression of CD44 can be used as an important indicator for breast cancer chemotherapy.
5.Diagnostic Value of Rv0222/ESAT-6 Fusion Protein in Tuberculosis
Huizhang ZHANG ; Qiwen FAN ; Hua YANG ; Hongmei HUANG ; Qiang FANG
Chinese Journal of Clinical Medicine 2014;(6):636-639
Objective:To explore the serodiagnostic value of Rv0222/ESAT-6 fusion protein in tuberculosis.Methods:By using purified recombinant Rv0222/ESAT-6 fusion protein as antigen and enzyme-labeled antibody as secondary antibody,the serum of patients with tuberculosis and patients with human immunodeficiency virus(HIV)accompanied by tuberculosis,non-tubercu-losis patients and healthy people were detected with enzyme-linked immunosorbent assay(ELISA).The diagnostic value of the fusion protein in tuberculosis was evaluated.Results:By setting T lymphocyte spot test of infection with Mycobacterium tuber-culosis (T-SPOT)as the gold standard,the sensitivity and specificity of ELISA,of which Rv0222/ESAT-6 fusion protein was used as the antigen,in the diagnosis of tuberculosis were 86% and 100%,respectively.There was no statistically significant difference in the positive rate of tuberculosis between T-SPOT and ELISA.Conclusions:The ELISA with Rv0222/ESAT-6 fu-sion protein as antigen,has certain application value in the serodiagnosis of tuberculosis.
6.The effects of GM1 and bFGF synergistically inducing adult rat bone marrow stromal cells to form neural progenitor cells and their differentiation.
Hui ZHANG ; Ji-zuo WANG ; Hong-yu SUN ; Jian-ning ZHANG ; Shu-yuan YANG
Chinese Journal of Traumatology 2004;7(1):3-6
OBJECTIVETo investigate the effects of GM1 on inducing adult rat bone marrow stromal cells (MSCs) to form neural progenitor cells and their differentiation.
METHODSPurified MSCs were induced by different components of basic fibroblast growth factor (bFGF) alone, GM1 alone or combination of bFGF with GM1. After 3 days' incubation, fibronectin and collagen I were detected with immunocytochemistry, and nestin was detected with immunofluorescence. Neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP) and galactose cerebroside (GalC) were detected with immunocytochemistry after 7 days' incubation.
RESULTSAfter induction with bFGF alone or combination of bFGF and GM1, some MSCs exhibited the phenotypes of neural progenitor cells, and then neurons and astrocytes. In these two groups, the positive cells for fibronectin and collagen I decreased markedly after 3 days' induction. At the same time, the positive cells for nestin increased markedly. After 7 days' induction, NSE and GFAP-positive cells increased significantly. Furthermore, the addition of bFGF and GM1 caused the maximal variation. However, addition of GM1 alone had no inductive effects.
CONCLUSIONSCombination of bFGF with GM1 may synergistically promote the transformation of MSCs and differentiation into neurons and astrocyte-like cells. The results suggest a promising route for the application of MSCs.
Analysis of Variance ; Animals ; Bone Marrow Cells ; Cell Differentiation ; drug effects ; physiology ; Cells, Cultured ; Drug Synergism ; Fibroblast Growth Factor 2 ; pharmacology ; Fluorescent Antibody Technique ; G(M1) Ganglioside ; pharmacology ; Immunohistochemistry ; Probability ; Rats ; Rats, Wistar ; Sensitivity and Specificity ; Stem Cells ; pathology ; physiology ; Stromal Cells ; drug effects ; physiology ; ultrastructure
7.CT Diagnosis of Ganglioneuroma
Ye TAN ; Zhenghan YANG ; Cheng ZHOU ; Min ZHANG ; Huizhang LI ; Xiangyang WANG ; Jiahu WEI
Journal of Practical Radiology 2001;0(06):-
Objective To investigate CT characteristics of ganglioneuroma.Methods CT findings in 12 patients with ganglioneuroma proved histopathologically were retrospectively analyzed.Results The lesions localized in the adrenal gland in 8,the retroperitoneum in 3,the posterior mediastinum in 1.eleven lesions appeared as homogeneous hypo-or isodense oval masses with well delineated margins and 1 was cysto-solid on plain CT scans.The calcifications were seen inside one tumor.On enhanced CT scans,the lesions were mild enhancement in 4,moderate enhancement in 3,significant enhancement in 3 and no enhancement in 2.Mild delayed enhancement in 5 cases,moderate delayed enhancement in 4 cases and no delayed enhancement in 3 cases were showed.Conclusion Typical ganglioneuroma shows low intensity,mild or moderate enhancement and delayed enhancement.

Result Analysis
Print
Save
E-mail